MDL 105519 is a potent and selective antagonist of glycine binding to theNMDAreceptor.

MDL 105519 is a potent and selective ligand for the glycine recognition site that completely inhibit the binding of [³H]glycine to rat brain membranes with a K_ivalue of 10.9 nM. MDL 105519 is approximately 10,000-fold selective for the glycine recognition site relative to the other receptor types investigated. MDL 105519 inhibits NMDA-dependent responses, such as elevations of [³H]TCP binding in brain membranes, cyclic GMP accumulation in brain slices, and alterations in cytosolic Ca²⁺and Na⁺-Ca²⁺currents in cultured neurons. Inhibition is non-competitive with respect to NMDA and could be nullified with D-serine^[1].

MDL 105519 is an NMDA receptor antagonistin vivo. Intravenously administration of MDL 105519 prevents harmaline-stimulated increases in cerebellar cyclic GMP content, providing biochemical evidence of NMDA receptor antagonismin vivo. This antagonism is associated with anticonvulsant activity in genetically based, chemically induced, and electrically mediated seizure models. Anxiolytic activity is observed in the rat separation-induced vocalization model, but muscle-relaxant activity is apparent at lower doses. Higher doses impair rotorod performance, but are without effect on mesolimbic dopamine turnover or prepulse inhibition of the startle reflex^[1].

376.19

Solid

C₁₈H₁₁Cl₂NO₄

161230-88-2

Room temperature in continental US; may vary elsewhere.

DMSO : 17 mg/mL(45.19 mM;Need ultrasonic and warming)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。